>B-crystallin (CRYAB) is a small heat shock protein with a chaperoning activity that is present in the postnatal healthy human brain in oligodendrocytes and in a few astrocytes. The involvement of CRYAB in cell differentiation, proliferation, signaling, cytoskeletal assembly, and apoptosis in various model systems has suggested that it might also play a role in the developing human brain. We analyzed the distribution and the levels of this molecular chaperone in healthy and polygenetically compromised (Down syndrome [DS]) human telencephalon at midgestation. We demonstrate that CRYAB is expressed in a temporospatial pattern by numerous radial glial cells and some early oligodendrocyte progenitors, including dividing cells, as well as a few astroglial cells in both healthy and DS fetal brains. We also found abundant phosphorylation of CRYAB at Ser-59, which mediates its antiapoptotic and cytoskeletal functions. There was only marginal phosphorylation at Ser-45. In contrast to our earlier study in young DS subjects, upregulation of phosphorylated CRYAB occurred rarely in DS fetuses. The distribution, the timing of appearance, and the results of colocalization studies suggest that CRYAB assists in the biological processes associated with developmental remodeling/differentiation and proliferation of select subpopulations of progenitor cells in human fetal brain at midgestation.
INTRODUCTION
Some heat shock proteins (HSPs) demonstrate very early expression in the embryos of diverse organisms and persist at the early stages of forebrain, midbrain, and hindbrain formation (1, 2) . >B-crystallin (CRYAB) is a member of a family of small HSPs, molecular chaperones with the molecular mass of subunits in the range of 12 to 43 kd (3, 4) . >B-crystallin, like some other small HSPs, not only is inducible by heat and other stress factors (5) but also is expressed constitutively in many tissues and organs, reaching the highest levels in the lens, heart, and skeletal muscles (6Y8).
In postnatal healthy human brain, CRYAB is present mostly in some oligodendrocytes and a few astrocytes (6, 9Y11) . Accumulation of CRYAB, predominantly in oligodendrocytes and astrocytes and less frequently in neurons, has been reported in numerous pathological conditions such as stroke, vascular/hypoxic encephalopathy, infectious and demyelinating diseases, leukodystrophies, neoplasms, primary neurodegeneration associated with abnormal protein aggregation, and epileptic foci (10, 12Y16) . >B-crystallin is also a component of cytoplasmic inclusions in various human disorders such as Alexander disease (9) , desminopathies (17) , tauopathies with glial pathology (15) , and multiple-system atrophy (18) .
The possible association of CRYAB with cell differentiation and developmental remodeling was suggested in earlier in vivo studies on chick embryos in which CRYAB appeared in cells of the notochord, lens, and myotome as soon as these cells migrated from the anterodorsal lip of the dermomyotome and were undergoing extensive morphological reorganization (19) . Experiments in vitro showed induction of CRYAB expression within 24 hours after transferring mouse C2C12 myoblasts to a differentiation medium and inhibition of differentiation-induced caspase 3 activation and myogenic differentiation of these cells by an overexpressed protein (20) . The role of >-crystallins in the remodeling of intermediate filaments during development and differentiation was suggested in experiments demonstrating that they inhibited the in vitro assembly of glial fibrillary acidic protein (GFAP) and vimentin and increased the soluble pool of GFAP when added to preformed filaments (21) . Phosphorylated forms of CRYAB were also detected in Copyright @ 2010 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
mitotic cells in various cell lines examined in vitro and in tissue sections of mouse embryos (22, 23) . Furthermore, a strong cytoplasmic immunostaining of CRYAB phosphorylated at Ser-45 was observed in nondifferentiated dividing cells forming neurospheres in vitro (24) . In agreement with its potential role in cellular differentiation and developmental remodeling, it was found recently that CRYAB interacts with important regulatory proteins implicated in cellular differentiation, proliferation, signaling, cytoskeletal assembly, and apoptosis such as fibroblast growth factor 2, nerve growth factor A, vascular endothelial growth factor, insulin, and A-catenin (25) .
Our previous study indicated the upregulation of phosphorylated CRYAB in the brains of children and young adults with trisomy 21, that is, Down syndrome (DS) (11) . Down syndrome is the most common noninheritable genetic cause of mental retardation in humans (26) . This observation and the results of studies pointing to the association of CRYAB with cell proliferation, differentiation, and developmental remodeling inclined us to explore its potential role in human brain development.
Radial glial cells (RGs), a progeny of the earlier neuroepithelial cells, play an important role in brain development. In human telencephalic ventricular zone (VZ), the first dividing RGs appear at 6 weeks of gestation (wgs), and in the subventricular zone (SVZ) and intermediate zone, at 9 to 10 wgs, becoming sparse at È24 wgs (27) . Cell bodies of these bipolar cells are located in the proliferative periventricular zones and make contact with the ventricular surface either directly or via a short apical process ending with a basal foot. Long, radial processes of RGs form enlarged end feet at the pial surface or terminate at the vascular walls at various levels of the cerebral hemispheres (28Y30). Involution of the ventricular processes of RGs that initiate the gradual transformation of these cells into astrocytes starts at 12 wgs but is most conspicuous during the second half of gestation (28, 31, 32) . In the adult brain, RGs persist only in small amounts in the SVZ of the lateral ventricle, the hippocampal dentate gyrus, and in modified forms, as the Bergman glia of the cerebellum, tanycytes of the hypothalamus, and Müller cells of the retina (30) .
On the basis of structural and molecular characteristics, RGs have traditionally been viewed as immature astroglia (28, 33) , the long processes of which guided young neurons migrating from the VZ to the developing cortex (33) . However, studies performed in the last decade (mostly in rodents) have demonstrated that RGs are mitotically active, pluripotent, heterogeneous progenitors generating cortical pyramidal neurons, macroglial cells, and ependymocytes in the prenatal/perinatal brain (30, 34Y37). The multipotent character of RGs also in human fetal brain was supported recently by studies showing that a portion of RGs isolated from the human cortical VZ/SVZ at midgestation generate in vitro astrocytes, a small number of neurons (38) , and oligodendrocytes (39) .
In this study, we investigated the distribution and the levels of CRYAB in the telencephalon of healthy and DS fetuses at midgestation. We also used phospho-specific antibodies to determine whether CRYAB is phosphorylated in human fetuses at Ser-45 and Ser-59, that is, 2 of the 3 sites potentially phosphorylated in CRYAB (22) . We found that CRYAB is expressed in the telencephalon of both healthy and DS fetuses, predominantly by RGs in the periventricular proliferative zones of the frontoparietal area. Some early oligodendrocyte progenitor cells (OPCs) and a few astroglial cells also showed CRYAB immunoreactivity. Our finding that CRYAB is expressed in a subset of progenitor cells (both RGs and early OPCs) in human fetal brain suggests a possible role for this stress protein in human brain development.
MATERIALS AND METHODS

Human Tissues
For immunohistochemistry (IHC) and immunofluorescence, formalin-fixed and paraffin-embedded brain tissue sections were obtained from the archives of the Department of Neuropathology of the Institute of Psychiatry and Neurology, Warsaw, Poland, and the Pediatric Neuropathology Laboratory at the Institute for Basic Research in Developmental Disabilities, Staten Island, New York. Coronal sections through the telencephalon at the level of the basal ganglia were accessible from 28 healthy fetuses at 11 to 26 wgs and 26 DS fetuses at 15 to 24 wgs. The age of the fetuses was based on the information about the last menstrual period of the mothers. Control fetuses were analyzed at 11 (n = 1), 14 (n = 1), 15 (n = 2), 16 (n = 2), 17 (n = 1), 18 (n = 5), 19 (n = 5), 20 (n = 4), 21 (n = 3), 22 (n = 2), 24 (n = 1), and 26 (n = 1) wgs. Down syndrome group included fetuses at 15 (n = 1), 17 (n = 1), 18 (n = 4), 19 (n = 8), 20 (n = 7), 21 (n = 3), 22 (n = 1), and 24 (n = 1) wgs. All brains were obtained after legal abortions (spontaneous abortions for control fetuses, and either spontaneous or induced prostaglandin abortions for DS fetuses). On autopsies, the brains revealed no gross pathology.
For immunoblotting analyses, frozen fetal brain tissues were provided by the Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD. The sections through the whole brain hemispheres at the level of basal ganglia were available from 3 control (at 19 wgs) and 3 DS fetuses (at 18Y22 wgs). The following brain areas were analyzed by immunoblotting: the white matter/ intermediate zone, the frontal cortex, and the periventricular area of the body of the lateral ventricle. The postmortem interval was from 1 to 4 hours.
The study was approved by the institutional review board of the Institute for Basic Research in Developmental Disabilities, Staten Island, New York. The diagnosis of DS was based on karyotyping and discovery of an extra chromosome 21. Genetic tests were not performed in control fetuses except for 3 cases used for immunoblotting that showed a normal chromosome complement.
Sodium Dodecyl SulfateYPolyacrylamide Gel Electrophoresis and Western Blot Analysis
Brain tissues were homogenized in a buffer containing 50 mmol/L Tris, pH 7.4, 1% sodium dodecyl sulfate, and protease inhibitor cocktail (Complete; Roche Applied Science, Indianapolis, IN) supplemented with 2 Kmol/L pepstatin A and 1 mmol/L sodium orthovanadate, 2 Kmol/L cyclosporine A, and 0.2 Kmol/L okadaic acid (inhibitors of phosphatases; Sigma-Aldrich, St Louis, MO), then sonicated and centrifuged at 15,000 Â g for 5 minutes. The protein content of the supernatant was measured by using the Coomassie (Bradford) protein assay kit (Thermo Fisher Scientific, Rockford, IL) and bovine serum albumin as a standard. Protein (20 Kg per lane) was loaded onto 10% Tris/Tricine gels, electrophoretically separated, electrotransferred onto nitrocellulose membranes, and developed by using the chemiluminescence method, as described (40) . To confirm equal protein load, immunoblots were stripped and reprobed with monoclonal antibodies (mAbs) to A-actin, diluted 1:50,000 (Sigma-Aldrich). Densitometry analysis of Western blots was performed by using 1Dscan EX software (Scanalytics, Inc, Fairfax, VA). The 2-tailed Student t test for independent samples was used to assess the statistical significance of data, with p G 0.05 as the level of significance.
Immunohistochemistry
Six-micrometer-thick sections were deparaffinized in xylene, rehydrated in graded alcohol series, and washed extensively with water. For antigen retrieval, sections were boiled 3Â 5 minutes in 10 mmol/L citrate buffer, pH 6.0, in a microwave oven and then cooled for 20 minutes at room temperature. Afterward, endogenous peroxidase activity was blocked with 0.3% H 2 O 2 in methanol for 20 minutes, and nonspecific binding sites were then blocked with 10% fetal calf serum (FCS) in phosphate-buffered saline (PBS). Tissues were stained with mAbs or polyclonal antibodies (pAbs) to CRYAB (Assay Designs, Victoria, Canada; at 2 Kg/mL) or pAbs to CRYAB phosphorylated either at Ser-59 (Ser59P + , at 2 Kg/mL; Assay Designs) or at Ser-45 (Ser45P + ; at 2 Kg/mL [Assay Designs] and at 8 Kg/mL [Sigma-Aldrich]). The incubation with primary antibodies diluted in 10% FCS in PBS lasted overnight at 4-C. Afterward, the sections were incubated with biotinylated speciesY specific secondary antibodies (GE Healthcare, Piscataway, NJ) diluted 1:200 and then with ExtrAvidin peroxidaseY conjugated (Sigma-Aldrich), diluted 1:400, both for 1 hour at room temperature. Diaminobenzidine (0.5 mg/mL) in the presence of 0.03% H 2 O 2 was used as a chromogen. Sections were lightly counterstained with hematoxylin. Method controls included omission of the primary antibodies and preincubation of the pAbs to phosphorylated CRYAB with an excess (30 Kg/mL) of adequate synthetic phospho-peptides: either L(pS)PFYLRPPSF (Ser45P 
Immunofluorescence
For double and triple immunolabeling, after antigen retrieval and blocking of nonspecific binding sites with 10% FCS in PBS, as previously mentioned, sections were incubated overnight at 4-C with mAbs or pAbs to CRYAB, and pAbs to GFAP raised either in rabbits (at 1:400 [DAKO, Carpinteria, CA] or at 1:1000 [Chemicon, Temecula, CA]) or guinea pig (at 1:100; Acris, Hiddenhausen, Germany), rabbit pAb to platelet-derived growth factor receptor > (PDGFR>, at, 1:80; Thermo Fisher Scientific, Fremont, CA), rabbit pAb to A-tubulin III (at 1:200; Sigma-Aldrich), and rabbit mAb to heat shock factor 1 (HSF1, at 1:200; Novus Biologicals, Littleton, CO), all diluted in 10% FCS in PBS. After several rinses in PBS, sections were incubated for 1 hour at room temperature with species-specific secondary antibodies conjugated with fluorescent dyes: Alexa Fluor 555 (red; diluted 1:2000) and Alexa Fluor 488 (green) or Alexa Fluor 633 (blue) diluted 1:1000 (Invitrogen/Molecular Probes, Eugene, OR). Some double-labeled sections had nuclei counterstained with TO-PRO-3 iodide (blue; Invitrogen/Molecular Probes). Sections were washed in PBS, mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA), and viewed with a Nikon C1 laser scanning confocal system mounted on a Nikon 90i microscope (Nikon Instruments Inc., Melville, NY). Optical images were processed by using Adobe Photoshop 6.0. Omission of the primary antibodies was used as a control of the method.
RESULTS
>B-crystallin+ cells were detectable in human fetal telencephalon throughout all of the gestational ages analyzed, but their numbers and distributions showed distinct temporospatial differences (Table) . There was also some interindividual variability regarding the number of immunostained cells in a given brain area, but the general immunostaining patterns were comparable each gestational age.
At 11 wgs, CRYAB+ cells occupied a small region of the VZ/SVZ of the lateral ventricle at the border between the distal part of the dorsal hippocampal primordium and the fornix (Figs. 1A, arrows, 2A ). Immunoreactive processes of these cells extended to the subpial area. Later, the number of CRYAB+ cells increased in the VZ/SVZ of the body of the lateral ventricles and were most abundant in this brain area at 18 to 21 wgs (Fig. 1B, arrows) . From approximately 15 to 18 wgs, some immunoreactive cells also were seen in the marginal zone of the indusium griseum (Fig. 1B, arrowhead) , the callosal sling (Fig. 1B, open arrow) , the temporal VZ (not shown), and the marginal zone (MZ) of the hippocampus (Fig. 1C, arrows) , the fimbria/fornix (Fig. 1C, open arrow) , and the dentate gyrus and fimbrial bundle (Fig. 1D, arrows) .
In the VZ/SVZ of the body of the lateral ventricle, immunopositive cells were present in all fetuses we studied, and they followed dorsal-to-ventral and inward-to-outward gradients. Immunoreactivity appeared first in cells at the dorsal hippocampus/fornix border, then in cells of the callosal glioepithelium and cingulate neuroepithelium, followed by numerous cells lining the whole body of the cortical VZ/SVZ at 18 to 21 wgs. As the ependymal cells were emerging in the dorsal VZ, CRYAB+ cells disappeared in this area (Figs. 1B, 2C, D), becoming the most abundant in the ventral VZ/SVZ adjacent to the GE at 22 to 24 wgs. Delicate processes of CRYAB+ cells often terminated around the primitive blood vessels in the SVZ. In younger fetuses, immunopositive cells and their processes were densely packed at the ventricular border (Figs. 2A, 3AYC ), whereas in older fetuses, they were more loosely distributed, being more numerous in the deeper layers of the VZ (Figs. 2B, 3DYF ) and in the SVZ (Figs. 2B,  3GYI ). Some mitotic cells located at the ventricular border of the VZ in both younger and older fetuses displayed CRYAB immunoreactivity as well (Figs. 2A, B, arrows) . At 26 wgs, CRYAB+ cells were scarce in VZ, persisting in small amounts in the SVZ (Fig. 2E, arrows) .
In the temporal VZ/SVZ, CRYAB+ cells were present in small numbers and in only 5 of 20 fetuses with the temporal lobe available (not shown). >B-crystallin+ cells also were present in the hippocampal MZ, in 13 of 20 fetuses with hippocampi accessible. In this area, CRYAB+ cells were less numerous than in the frontoparietal VZ/SVZ, and only individual immunopositive cells on the whole cross section of the hippocampus were seen in 6 fetuses (not shown). The most prominent immunostaining in the hippocampal MZ is presented in Figure 1C (red arrows). Cells of the GE did not show CRYAB immunoreactivity (Figs. 1A, C) .
The morphology of CRYAB+ cells varied (Figs. 2, 3 ). In the VZ, immunopositive cells showed either unipolar or bipolar morphology (Figs. 2A, B, D, 3AYF ). Bipolar cells had strongly immunoreactive apical processes forming a large end foot at the ventricular surface. Their basal processes were visible mostly in the SVZ, and less frequently in the intermediate zone/white matter (Figs. 2B, D, 3AYI ). Elongated cells with strong immunoreactivity confined mostly to the cytoplasm also were encountered in the VZ/SVZ. In the SVZ, the most common were polygonal cells with delicate, varicosity-bearing processes (Fig. 2F, arrows) , or larger cells with elongated somata and a few, short processes (Figs. 4GYI) . In other brain areas, either large cells with light nuclei (Fig. 2G, arrow ) or smaller cells with elongated somata (Fig. 2G, arrowhead) , both with simple multipolar morphology, were present.
In many immunopositive cells and their processes in various brain areas, the reaction product was not uniformly distributed in cell cytoplasm; instead, it formed granules of various sizes located at the periphery of the cell somata or alongside the processes (Figs. 2G, H, short arrows) . These immunopositive granules also were seen in the large, oftentimes dividing, cells present at 20 to 22 wgs in the frontal white matter (Fig. 2I, short arrows) .
To further characterize the types of cells expressing CRYAB, we used double-and triple-labeling experiments with antibodies to CRYAB and to GFAP, an astrocyte and RGs marker (41) , to A-tubulin III, a marker of young postmitotic neurons (42), or to PDGFR>, a marker of early OPCs (43, 44) .
Double-labeling experiments demonstrated that bipolar and unipolar CRYAB+ cells that were located in the cortical VZ/SVZ and contained a long process directed toward the SVZ coexpressed GFAP (Figs. 3AYI) , thus corresponding to RGs. Radial glial cells colabeled with antibodies to CRYAB and GFAP were the most abundant in the VZ/SVZ of the body of the lateral ventricle at 18 to 21 wgs. Although it was not a rule, those RGs that showed the strongest CRYAB immunoreactivity, especially in older fetuses, oftentimes showed weaker immunostaining to GFAP than did adjacent cells (Figs. 3DYF, open arrow) . Furthermore, within individual immunopositive RGs, GFAP and CRYAB immunoreactivity often could be seen in different areas of the cell cytoplasm or processes (Figs. 3DYF, arrows, arrowhead) . Strong CRYAB immunostaining was present in numerous end feet of RGs at the ventricular surface (Fig. 3D, arrowhead) . Antibodies to GFAP also labeled CRYAB+ mitotic cells located at the ventricular border (Figs. 3AYC, arrowheads), as well as elongated and multipolar cells distributed along the long array of cells in the cortical SVZ (Figs. 3AYC,  GYI, arrows) . Numerous CRYAB+ cells located in brain regions other than the cortical VZ/SVZ also demonstrated GFAP immunostaining (Figs. 3J, K, arrows) .
Cells expressing A-tubulin III in the VZ/SVZ did not show CRYAB immunoreactivity (Figs. 4AYC) , indicating that newly born neurons do not express CRYAB. However, many CRYAB+ cells coexpressed PDGFR>, suggesting that CRYAB is present in some early OPCs. The cells coexpressing CRYAB and PDGFR> were the most numerous in the callosal and cingulate SVZ (Figs. 4DYI, arrows) and the fimbria/fornix (not shown), but they were also seen in small numbers in other regions of the telencephalon where CRYAB+ cells were present and, occasionally, even in the VZ (Figs. 4JYL, arrows) . Unexpectedly, triple-labeling experiments with the use of antibodies to CRYAB, GFAP, and PDGFR> revealed that most CRYAB+/PDGFR>+ cells were also GFAP+ (Figs. 5AYD, arrowheads) , and a few cells coexpressed only CRYAB and GFAP (Figs. 5AYD, arrows) .
The expression of HSP is regulated by transcription factors belonging to a family of HSFs, and the activity of one of these factors, HSF1, seems to be essential for constitutive expression of some HSPs, including CRYAB (45) . Therefore, to address the issue of whether the expression of CRYAB in human fetal brains might be constitutive, we next performed a colocalization study of HSF1 and CRYAB. All CRYAB+ cells revealed HSF1 immunostaining (Figs. 5EYG) , but the intensity of immunoreactivity varied; HSF1 immunoreactivity was very strong in some CRYAB+ cells, whereas in some other cells, it was confined to a few positive dots only (arrows in Figs. 5EYG).
Because our earlier studies showed upregulation of CRYAB phosphorylated at Ser-45 and Ser-59 in the brains of older children and young adults with DS (11), we compared the levels and distribution of CRYAB and its forms phosphorylated at Ser-45 and Ser-59 in healthy and DS fetal brains using immunoblotting and IHC. By IHC, the pattern of CRYAB immunostaining was similar in healthy and DS fetuses, although it seemed that CRYAB+ cells were more abundant in the periventricular proliferative zones in DS than healthy fetuses (Fig. 6A) . However, in immunoblots of tissue homogenates from the frontoparietal VZ/SVZ at 18Y22 wgs, no significant differences in CRYAB levels were found between 3 healthy and 3 DS fetuses (Fig. 6B) .
By IHC, CRYAB phosphorylated at Ser-59 appeared in all cell types showing CRYAB immunoreactivity in both healthy and DS fetal brains (Fig. 6C) . In 2 DS fetuses (at 18 and 19 wgs), CRYAB Ser59P + immunoreactivity was stronger and more widespread than in all other subjects analyzed (not shown). By immunoblotting, however, there were no significant differences in the levels of CRYAB Ser59P + in the frontoparietal VZ/SVZ between the 3 healthy and 3 DS fetuses (Fig. 6D) .
In contrast to CRYAB Ser59P + , immunoreactivity to CRYAB Ser45P + was visible in only a few cells in both healthy and DS fetal brains (not shown). The reaction product was often coarsely granular. Some dividing cells at the ventricular border of the cortical VZ also were immunoreactive (not shown), in agreement with data showing that phosphorylation of Ser-45 is enhanced during cell divisions (22) . There was no signal to CRYAB Ser45P + on immunoblots from VZ/ SVZ, confirming a weak expression of CRYAB Ser45P + in fetal human brains shown by IHC. >B-crystallin Ser45P + and Ser59P + immunoreactivities were abolished after preincubation of the primary antibody with an excess of the adequate phospho-peptide (not shown). There were no CRYAB+ signals on immunoblots from the cortex and intermediate zone of fetal brain tissues, reflecting the paucity of CRYAB+ elements in these regions at midgestation.
In the oldest fetuses examined, immunoreactivity to CRYAB appeared in a few cells located in the subpial areas, the white matter, the neocortex, and the hippocampus and numerous cells in the ventral corpus callosum. Small petechiae and hemorrhages in the GE, without hemosiderin or any marked reaction in the adjacent tissue, were commonly observed.
DISCUSSION
Our study revealed that CRYAB is expressed in a temporospatial pattern by numerous RGs, some early OPCs, and a very few astroglial cells in both healthy and DS human fetal telencephalon at midgestation. The lack of significant pathological changes in the tissues we analyzed, the similar pattern of immunoreactivity among fetuses, and the colocalization of CRYAB with HSF1 all support the idea of constitutive expression of CRYAB in human fetal brains. At the same time, however, there were some interindividual differences in numbers of CRYAB+ cells in the same brain area (e.g. temporal VZ/SVZ and hippocampal MZ), suggesting the possible contribution of additional, as yet undefined, factors in the induction of CRYAB expression.
To our knowledge, this is the first characterization of CRYAB localization in human fetal brain tissues. In their recent article, Sarnat and Flores-Sarnat (16) could not detect CRYAB immunoreactivity in human fetal brains. However, we found that the use of the antigen retrieval method was critical for detecting CRYAB in formalin-fixed, paraffinembedded fetal brain tissues, and this step was not included in the IHC protocol used by these authors, which may have contributed to the lack of CRYAB immunostaining in their study.
We found that CRYAB is expressed abundantly by RGs in the VZ/SVZ of the body of the lateral ventricle at midgestation. Given that i) CRYAB is expressed mostly by oligodendrocytes in the postnatal human brain, ii) some RGs in the cortical VZ/SVZ can be labeled with markers of early OPCs (39, 46) (Fig. 4) , and iii) recent in vitro experiments showed that some cortical RGs may generate oligodendrocyte lineage cells (39) , our data might indicate CRYAB expression in RGs undergoing oligodendrocyte lineage specification. However, this interpretation is challenged by at least 2 of our findings. First, although in our study, RGs expressing CRYAB prevailed in the cortical VZ/SVZ at midgestation, it was estimated recently that only a small proportion of the cortical RGs could generate oligodendrocytes (39) . Second, there was a discrepancy between the abundance of CRYAB+ RGs in the cortical VZ/SVZ and the scarcity of CRYAB+ early OPCs. Thus, it is more plausible that only a subpopulation of CRYAB+ RGs can represent oligodendrocyte lineageYcommitted cells, suggesting that CRYAB is also expressed by numerous RGs not involved in the generation of OPCs.
We found that CRYAB+ RGs, including dividing cells, were the most numerous cells in the proliferative zones of the body of the lateral ventricle and were scarce or absent in the periventricular proliferative zones in other brain regions. Whether this topography reflects the sensitivity of RGs located in the VZ/SVZ of the body of the lateral ventricle to physiological stress conditions and/or their specific requirements must be addressed by future studies. The particular vulnerability of OPCs in this area to anoxia/ischemia is well documented; the periventricular frontoparietal area is the predilection site for the periventricular white matter injury, the leading cause of chronic neurological disability in survivors of premature birth (47) . Nevertheless, because the most prominent expression of CRYAB by RGs located in the VZ/SVZ of the frontoparietal area coincided with the periods of extensive remodeling of these cells and generation of oligodendrocyte progenitors, ependymocytes, and astrocytes, it is also reasonable to propose that CRYAB could be engaged in the biological processes associated with differentiation and developmental remodeling of a subpopulation of RGs in the developing human brain.
Sequential progression of the oligodendrocyte lineage proceeds through the stages of the early OPCs, preoligodendrocytes, and immature/premyelinating oligodendrocytes, which differ by morphological features, proliferative and migratory capacity, and antigenic profiles from the mature/ myelinating oligodendrocytes predominating in the adult brain (47, 48) . The PDGFR> is a powerful mitogen, stimulating proliferation, motility, and survival of OPCs (48), and is widely used as a marker for early OPCs (43, 44, 49) . Furthermore, conditional ablation of PDGFR> in a subpopulation of postnatal cells showed that this receptor is required for oligodendrogliosis (50) . Therefore, on the basis of morphology and antigenic profile, we categorized the cells coexpressing CRYAB and PDGFR> as early OPCs.
In the human telencephalon studied at midgestation, the population of proliferative, migratory cells labeled with antibodies specific for early OPC seems to have at least 3 sources of origin: the cortical SVZ and the SVZ of the lateral and medial GE (43, 51, 52 ). In our material, CRYAB immunoreactivity was present only in a small subset of early OPCs, most often those located in the cortical SVZ, the ventral corpus callosum, the fimbria/fornix, and the dentate gyrus. Therefore, it seems that only specific subsets of early OPCs and in unique brain regions require the function of CRYAB in fetal life. Because OPCs are highly sensitive to various deleterious insults such as oxidative stress or glutamate-related excitotoxicity (48) , it is possible that CRYAB induction might protect these cells during the early stages of differentiation and/or migration to the final location.
Interestingly, most cells labeled with antibodies to PDGFR> and CRYAB were also GFAP+. Morphology and this particular antigenic profile suggest that these cells may represent very early stages of oligodendroglial lineage specification. Furthermore, expression of GFAP by these cells points to their possible RG origin. However, another possibility implying that at least some CRYAB+ cells coexpressing GFAP/PDGFR> are not yet lineage committed cannot be excluded. That some of these cells might survive into postnatal life was suggested by our earlier study demonstrating a small subset of cells coexpressing these 3 proteins in the brains of infants and young children, mostly in subpial and subependymal areas (11) . Experiments demonstrating the potent survival/proliferationYpromoting properties of CRYAB (20, 53, 54) and the fact that some B cells located in the adult SVZ expressing GFAP and PDGFR> function as primary progenitors (50) collectively support this hypothesis.
>B-crystallin is engaged in many vital biological processes. Because of its chaperoning activity, it prevents protein aggregation by maintaining proteins in a folding-competent state under various stress conditions (55, 56) and assists not only in the maintenance of cytoskeletal integrity via interactions with intermediate filaments and microtubules but also in the disassembly and reorganization of the cytoskeleton (21, 57Y61). Because of its role in the ubiquitin/proteasome pathway of protein degradation (62) , CRYAB is engaged in cell cycle progression assisting in ubiquitin-dependent degradation of cyclin D1 (63) . Via sequestrating proapoptotic Bax, Bcl-x s , and p53 and preventing their translocation to mitochondria (64) and by counteracting the proteolytic activation of procaspase-3 (54), CRYAB also confers resistance of the cells to various proapoptotic stimuli such as oxidative stress and reactive oxygen intermediates (65) . Future studies will need to determine which of the specific activities of this multifunctional protein are used in human fetal brain but the timing of expression, topography of CRYAB+ cells, and the results of colocalization studies point to specific chaperoning requirements of select human progenitor cells during their proliferation, cytomorphological reorganization, and migration.
>B-crystallin is phosphorylated at Ser-19, Ser-45, and Ser-59 (22, 66) . >B-crystallin phosphorylation occurs under physiological conditions in vivo and can be stimulated by various types of stress (66) . Phosphorylation of Ser-45 is catalyzed by p44/42 mitogenYactivated protein kinase, whereas mitogenYactivated protein kinaseYactivated protein kinase 2 catalyzes phosphorylation of Ser-59 (22) . Our earlier study showed abundant phosphorylation of CRYAB at Ser-59 already in infant brain and very weak phosphorylation at Ser-45 later in childhood (11) . Our present work extended these data, showing that phosphorylation of CRYAB, predominantly at Ser-59, occurs in the human telencephalon in early fetal life.
Although the results of the studies analyzing the role of CRYAB phosphorylation are not often consistent, they clearly demonstrate that phosphorylation significantly modifies the structure and the activity of CRYAB (67, 68) . Importantly, phosphorylation at Ser-59 reduced the inhibitory effect of synthetic peptide encompassing amino acid residues of 53 to 82 of the murine CRYAB sequence on actin polymerization in vitro (59) . Induction of CRYAB phosphorylated specifically at Ser-59 and association of the thus phosphorylated protein with cytoskeletal components was observed in cultured cells after stresses of the cytoskeleton, probably acting as a protective effector of the cytoskeleton (69) . Furthermore, mimicking phosphorylation of CRYAB on Ser-59 was necessary and sufficient to confer caspase-3 inhibition and protection of primary neonatal cardiac rat myocytes in vitro against apoptosis caused by hyperosmotic or hypoxic stress (70) . Thus, at least 2 activities of CRYAB that are important for cell remodeling and survival (i.e. modification of the cytoskeleton and antiapoptotic function) might be enhanced in the human fetal brain because of the phosphorylation of Ser-59.
Although we found more widespread immunoreactivity to CRYAB in some DS fetuses than in controls, these differences were not sufficiently large to be confirmed by immunoblotting. Upregulation of CRYAB phosphorylated at Ser-59 also represented an inconsistent feature in the group of DS fetuses and was observed only in individual subjects FIGURE 6 . >B-crystallin (CRYAB) distribution and levels in cortical ventricular/subventricular zone of the body of the lateral ventricle of healthy and Down syndrome fetuses at midgestation. Similar distribution (A, C) and levels (B, D) of CRYAB and CRYAB Ser59P + , respectively, in frontoparietal periventricular proliferative zone of healthy and Down syndrome fetuses. In panels B and D, immunoblots from the periventricular frontoparietal proliferative zone are shown in the upper panels and diagrams presenting densitometry analyses of immunoblots in lower panels. Blots were reprobed with monoclonal antibodies to A-actin. C, normal control fetus; DS, Down syndrome subject; wgs, weeks of gestation. Scale bars = (A, C) 40 mm.
by IHC. This is in agreement with our previous studies showing only a slight nonsignificant increase in CRYAB phosphorylation at Ser-59 in infants and young children with DS in comparison with controls and in contrast to the group of older children and young adults with DS in whom the levels of CRYAB Ser59P + were 130% higher than those in controls (11) .
Given the important roles of RGs in human brain development, our results raise the intriguing possibility that congenital CRYAB deficiency might lead to brain malformations by affecting the functions of RGs. However, naturally occurring mutations in the CRYAB gene reported to date in humans are associated with cataracts, dilated cardiomyopathy, myofibrillar myopathy, or a combination thereof (17, 71) . Neurological manifestations suggesting CNS involvement have not been observed in affected individuals. Because the negative effects of disease-associated mutations in CRYAB result mostly from a dominant gain-of-function with abnormal protein aggregation, as the most commonly observed phenomenon (72Y74), it is possible that the role(s) played by CRYAB in the developing human brain are preserved in affected individuals or are compensated for by other HSPs.
The complexity and protracted development of the human telencephalon and important differences between oligodendrogenesis and astrogliogenesis in primates and rodents call for caution in extrapolating results from animal models to human brain. For example, myelinogenesis begins in the third trimester of gestation in the human brain (75) , but in the second postnatal week in rats (76), and GFAP is expressed by human RGs from 5 wgs (41), but only perinatally in rodent RGs (77) . Nevertheless, animal models can provide more insight into the potential role of CRYAB in brain development.
It is well documented that developmental abnormalities occur in the brain of both HSF1 and HSF2 knockout mice (78Y80). Interestingly, some of the pathological changes observed in HSF1 knockout mice such as severe enlargement of lateral ventricles with only slightly enlarged third ventricle (80) or the enlargement of the lateral ventricle (78) and the reduced number of radial glia cells (79) in HSF2 knockout mice strikingly resemble the topography of the CRYAB expression we found in human fetuses. Whether CRYAB contributes to the pathology of HSF1 and HSF2 null mice must be elaborated by further studies. Downregulation of CRYAB has already been disclosed in the brains of HSF1 null mice (80) . Double-knockout mice generated by disrupting the gene for CRYAB and closely located HSPB2 (81) as well as transgenic mice overexpressing CRYAB (72, 82) have previously been used mostly to analyze its role in the eye and skeletal and cardiac muscles. That CRYAB might also play an important role in the brain tissue is indicated by experiments demonstrating that double-knockout mice develop worse experimental autoimmune encephalomyelitis and more marked apoptosis in astrocytes isolated from the pups on tumor necrosis factor or staurosporine stimulation than their wild-type counterparts (83) . Because HSPB2 is not normally expressed in the brain, these studies evidenced antiinflammatory and antiapoptotic function of CRYAB in the brain. Furthermore, CRYAB deficiency exacerbated the Alexander disease phenotype, although its astroglial overexpression rescued the mice from the otherwise lethal effects of GFAP mutation and excess in mouse models of Alexander disease, indicating that CRYAB plays a critical role in tempering Alexander disease pathology (84) . A detailed neuropathological analysis of CRYAB knockout mice, which might be helpful in elucidating the putative role of CRYAB in the brain development and neuropathology of HSF1 and HSF2 null mice as well, has not yet been published.
Collectively, our present study demonstrates that CRYAB is expressed, in a temporospatial pattern, by numerous RGs, some early OPCs and a few astrocytes in both healthy and polygenetically compromised human fetal brain, implicating CRYAB in the biological processes associated with proliferation and developmental remodeling/differentiation of subpopulations of progenitor cells in the developing human brain.
